Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Analysts remain bullish on AAPG: Ten brokerages give Ascentage Pharma an average “Buy” rating, including eight buys and two strong buys. The average 12-month price target is $46.43, well above the reported $16.90 share price.
• Recent financial results showed a loss: The clinical-stage biotechnology company reported quarterly EPS of negative $0.65 on revenue of $22.24 million, while analysts expect a full-year loss of $2.26 per share.
• Institutional interest has increased: HSBC and Citadel Advisors initiated positions, while UBS raised its stake by 149.4% during the latest reported periods.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) has been assigned an average recommendation of "Buy" from the ten brokerages that are currently covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $46.4286.

Several research firms have commented on AAPG. Raymond James Financial reissued a "buy" rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. BTIG Research reaffirmed a "buy" rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a "buy" rating and a $45.00 price objective for the company.

Ascentage Pharma Group International Trading Up 0.7%

Shares of AAPG stock opened at $16.90 on Thursday. Ascentage Pharma Group International has a 1 year low of $16.36 and a 1 year high of $42.48. The stock has a fifty day moving average of $18.18 and a two-hundred day moving average of $21.04. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million during the quarter. Equities analysts forecast that Ascentage Pharma Group International will post -2.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000. UBS Group AG boosted its holdings in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company's stock worth $716,000 after buying an additional 10,988 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International during the third quarter worth approximately $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source